Northwest Biotherapeutics Inc (QB) (NWBO) Quote

How long have you been spreading BS? Eight years? What a waste!

Haha Vegas has it at 1,000 to 1 against an update from the mute nonmanagement crew. I'll take that bet.

(Sigh.) Another week gone by (including Sept. 17)...isn't it time for management to give us an update?

Complete and total nonsense, pulled straight out of your butt.

learningcurve2020,

Sorry if you couldn’t keep up. I do get in too much of a rush sometimes that leaves too many thoughts jammed together if I don’t review before sending. That is a well documented fault that I thank you for reminding me of so that I can be more careful next time; ). Best wishes.

Reefrad,

That is exactly the correct answer!; ). Until the breakthrough comes the burden of carrying the load and the perceived inequity of management gaining so many shares is rather obvious and can’t be ignored completely. However, when the breakthrough comes and the potential begins to be realized the retrospect view will see the burden as having been worth it and management motivated not to sell out cheap. Best wishes.

I don’t deny the facts . I seriously wish there was less red tape and less Bureaucracy so that the patients can get the treatment fast enough and lots of lives are saved . I am all for it and seriously feel for the loved one’s .
The whole discussion was that you can not ignore the fact that one of the major reasons people invest money ( including their retirement money) in stocks is for it to appreciate and get ROI as expected which is based on various things which may have been said or implied over a decade .

I think you have a point here. you may be correct that nwbo has treated over 1000 patients in the compassionate care program. Wouldn't it be nice if the ceo would tell us that figure. How do you have a ROI metric on NWBO before it can sell, manufacture and distribute a product? Furthermore if ROI was indeed your investment metric, how could you have invested in NWBO at all?

I'm a no-body with limited investment knowledge, but regarding NWBO there are several questions that one must answer:

1. Does DCVax work, can it get approved? It does and will.
2. Can DCVax be manufactured to scale efficiently? It can (i,e. Flaskwork, CRL).
3. Will there be significant demand for DCVax? Hell yes!
4. Is the product protected from the greedy, sticky-fingered BPs who would steal the product if the could? Yes, vai patents and exclusive marketing rights.
5 Do you have the time for the company to accomplish 1 and 2? At the moment, now that MHRA/MAA has been filed, Hell yes!

I am more sure of my NWBO investment that I have every been.

manibiotech,

Life and death decisions are being made by enforcement of “the process” and leaving patients no choice when they should have one. This is tantamount to homicide which some use “the process” to justify. However, when you run the numbers of patients who would be effectively cured if treated with L bs not being treated there is a problem with trying to justify “the process” when a new paradigm of safe and effective treatment has emerged. So yes, I use the word homicide because patients are being kept from life saving treatment because there are those justifying this based on upholding “the process” that keeps a significant group of patients from what would keep them alive because there are economic considerations.
You are certainly well aware of how automobile recalls are done based on cost of payouts vs cost of recall. It’s an economic decision by many companies based on the dollar value of lives impacted or lost. Regulators of drugs and other treatments are charged with first “do no harm” when considering new treatments and care of patients. That is a little different than what auto manufacturers and laws surrounding them are charged with so when I talk about regulators with regard to “the process” I am pointing out their accountability to this charge.
So think about a current example with checkpoint inhibitors trying to move from IV administration to subcutaneous administration. Both carry a risk of death from use but subcutaneous injection so far has demonstrated an increased risk of death from use compared to IV administration in the attempt to demonstrate non inferiority of treatment effect. In Germany, this attempt to protect patent rights likely would face a huge hurdle since the increased risk of death from sub cutaneous administration would be a major concern. The question facing BMY and their December padufa date is will FDA be as concerned. I wonder if patients think they should be. I know I would be if I was a patient especially if a regulator is supposed to protect me against anything that would do more harm than an existing treatment. L is better than current SOC and in some cases might actually be more effective without part or all of SOC and the harm that does without improved outcomes in some patient subtypes. Best wishes.

Just a stream of nonsense without even the courtesy of paragraphs.

How come I don't even know if I get paid? You don't like my posts. You may think I am a liar. But the data are real. I share something I truly believe and I always cite some facts. What about you? You are spreading doubts, fabrications, and casting negativity. Do you know you are missing this once-in-a-life investment opportunity?

Here is the latest news. BMS keep laying off people. Have you noticed what kind of portfolio BMS have been building to fight cancer? It is precision medicine! My conjecture is that DCVax-L as a platform is essential for the development of precision medicine. Time will tell if my conjecture is right.

Bristol Myers Squibb axes 79 more in New Jersey as $1.5B cost-reduction program rolls on
https://www.fiercepharma.com/pharma/bristol-myers-squibb-axes-79-more-nj-15b-cost-reduction-program-rolls

The “majority” of the savings from the Strategic Productivity Initiative—as it has been dubbed by the company—“will be reinvested to fund innovation and drive growth,” a BMS spokesperson wrote in an email Friday.

“As part of this initiative, the company is focusing resources on R&D programs with the potential to deliver the greatest return on investment, prioritizing investing in key growth brands and optimizing operations across the organizations,” BMS' spokesperson added.

Explore our comprehensive approach to cancer research
https://www.bms.com/media/media-library/scientific-media-resources/our-comprehensive-approach-to-cancer-research.html

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175051962

Dodge.

suit,

What are you talking about? That post is of great interest to NWBO investors.

The trials that are linked are two PII trials involving dendritic cell vaccination in combo with pembrolizumab. These two studies are highly relevant and quite significant for NWBO (the two Roswell studies below are in addition to the ongoing UCLA study for rGBM that also includes pembrolizumab).

The United States Department of Defense is listed as a collaborator on one of the Roswell trials, and Merck’s pembrolizumab is being used in both of these studies.


https://clinicaltrials.gov/study/NCT04348747


https://clinicaltrials.gov/study/NCT05539365



https://physicianresources.roswellpark.org/news/roswell-park-clinical-trials-offer-novel-immunotherapies-for-advanced/metastatic-tumors-refractory-melanoma




https://www.prnewswire.com/news-releases/northwest-biotherapeutics-announces-exclusive-in-license-of-portfolio-of-dendritic-cell-technology-and-intellectual-property-302174237.html

“The license includes 5 new patent families that were just filed in 2023 and hence have their full potential patent life ahead of them. The technologies include enhanced versions of dendritic cells (DCs) and DC based therapies, as well as conditioning regimens designed to enhance patient responses and approaches to reprogram the tumour microenvironment to boost immune therapies and help overcome resistance to checkpoint inhibitors.

The DC based therapies include versions with tumour antigens loaded into the DCs and versions for intra-tumoural administration without pre-loading of antigens. Phase 2 trials involving the licensed technologies for two different cancers opened for enrollment earlier this year and are currently under way, and a third phase 2 trial for a third cancer is pending. The trials are fully funded by grant funding and are being conducted as investigator led trials. The company does not anticipate having to provide any funding or undertake any operational role for these trials.

As previously reported, over time the company has been quietly in-licensing various technologies and IP from various institutions and entities which it believes can be valuable in building a leading franchise in dendritic cell therapies.

The portfolio in-licensed from Roswell Park is complementary to, and builds upon, a portfolio which the company exclusively licensed from another institution last year. Together, the two portfolios encompass more than 20 years of work by one of the foremost groups of dendritic cell experts, led by Dr. Kalinski.

The portfolio in-licensed last year includes the foundational technologies and IP, and positive early-stage clinical trial results, developed by the Kalinski group over 17 years before coming to Roswell. The portfolio in-licensed now includes the further work during the last 7 years at Roswell. Taken together, the company believes that the two portfolios comprise a whole that is greater than the sum of its parts and offer compelling synergies with the company’s own portfolio. The company plans to collaborate with Dr. Kalinski on the further clinical development of the combined technologies.”

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175085456

The following are all the dendritic cell clinical trials sponsored by DoD. It seems like they all are connected to NWBO in some way. Did LP mention at ASM that NWBO has collaboration with academic institutions other than Roswell Park?

A First in Human Dose Escalation of… pic.twitter.com/IffpGJaBy1— d_stock (@d_stock07734) September 20, 2024

Bring it!

Please just stop, you are embarrassing. I know you are getting paid, but still bro.

The more these pumpers post non sense, the more it becomes clear that you don't want to be a bagholder after UK approval spike!

exwannabe,

Direct needed tech transfer and also has been improved upon which may require a new IND. in the mean time product release issues that will also affect Direct have been in process of being worked out both by NWBO and regulatory guidance. You know that NWBO wanted to include the Roswell Parks tech in the next iteration of Direct and that agreement has been worked on for the last 2 years. So you see, NWBO has been building up their relationship with MHRA through the Specials program which has provided substantial additional data from use of L outside the full parameters of the Phase 3 trial. That is going to help speed up all future trials and give MHRA a chance to really demonstrate leadership in a field that lays the groundwork for potentially all future cancer care treatment and beyond. Best wishes.

The present and future of bispecific antibodies for cancer therapy
https://www.nature.com/articles/s41573-024-00896-6

The above is a paper on t-cell engagers both approved and under clinical trials. All the targets adopted by those t-cell engagers can also be found on brain tumor cells from the poly-iclc trial. The interesting part is that it seems like HER2 needs to be taken care of specifically. Roswell looks like having some know-how to target HER2 specifically.









Dendritic Cell Vaccines Against Her2/?Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
https://clinicaltrials.gov/study/NCT04348747

Dendritic Cell-Based Treatment Plus Immunotherapy for the Treatment of Metastatic or Unresectable Triple Negative Breast Cancer
https://clinicaltrials.gov/study/NCT05539365

“ROI includes patient lives changed for the better. Others here share the same view. Best wishes.”

Here you clearly imply others meaning all others except you in common English . I don’t see “ some of us “ or “ many of us “ .

You start bringing up irrelevant and nonsensical topics like homicide , law etc etc in a simple discussion that the primary reason people invest in Wall Street is for ROI. But you go on irrational rant not relevant to this simple concept . But go right ahead .

JTORENCE,

Very likely true about what the Chinese would have done. Best wishes.

manibiotech,

Your “all” is not my “many”. Putting the word all in quotations and attributing it to me is misquoting me. I do not speak for all, rather for myself, but I do agree with many who are here and I do appreciate all honest opinions whether I agree with them or not, including yours. Best wishes.

I agree with you. At the same time if this thing ever succeeds we will be fine also. I know it doesn’t seem like it now but approval in the UK will turn everything around.

That's very believable

You are free to think what you like . I am fine with my belief

I think you are wrong.

And my point was …. Do you have problem if we who have invested hard earned money for more than 10 years get paid also
Please read before you post

Did you read the chain of posts I was responding to , or do you like shooting from the hip

The special programs share between jurisdictions. I am not saying We get an approval from FDA in less three. Months or less but faster than normal schedule. Keep this in mind this had happened before that a drug took less than usual time to get an approval from FDA or vise versa.

Zadie, Totally agree. An MHRA approval of DCVax first, puts pressure on every country to not be too far behind. Behind that pressure will be cancer patients, because knowledge of an efficacious, non-toxic, autologous, and broad-spectrum cancer vaccine will travel the globe quickly.

I also think governments and insurance companies will recognize the non-toxic nature of DCVax potentially reduces cancer and healthcare costs more broadly. Imagine the potential to avoid an entire layer of secondary treatments and costs resulting from side effects, of say chemotherapy (not a doctor, just did a quick look up on the web):

- extended hospital stays
- medications for nausea, vomiting, pain, infection (antibiotics), anxiety or depression
- medical procedures for blood transfusions for anemia
- nutritional support for weight loss, malnutrition
- skin care products for rashes and reactions
- wigs for hair loss
- mental health services for emotional
- home care services for fatigue
- transportation service for frequent treatment and follow-ups

You have a problem with them persevering for the last 15 years and getting paid for it?

Please explain what program you are referring to that would get it approved much faster?
There is AA, Rare disease to choose from.

Standard approval time frame is 9 to 10 months. AA is about 6 months.

So is that the reason management granted themselves millions of shares/options and then true up shares ?? That was above healthy salaries they were withdrawing .

But for rest of the mere mortals ROI is different

They have done this before to other drugs and this is not the first time.
Name one.

I didn’t say in my post they don’t file for FDA approval. They have to but FDA will have different view towards NWBO because of all related supportive programs between different jurisdictions. Instead of taking their sweet time let’s say 1 year it might be much faster. They have done this before to other drugs and this is not the first time.

Nonsense. The company has to file with the FDA first. Then and only then will the FDA look at the application. The FDA will consider that other countries have approved but will still look at the data. As I understand it, the FDA will consider the data provided as having been vetted, it will still require the data to demonstrate efficacy.

I am not suggesting that the data will not demonstrate efficacy. I am suggesting the FDA won't feel the pressure you suggest.

viagra didn't save anyone's life except of course yours, ex

ps
Now I get it why you are being such a d..k against NWBO. 😉

What a disingenuous post that ignores reality.

NWBO is a cash strapped company and has been for a long time.

NWBO chose to file in the country that has granted compassionate use for its treatment and has the most experience with the treatment. So yeah, they filed where they felt the likelihood of approval is the highest. That approval allows the company a revenue stream, a legitimization of its treatment MOA, and access to more funding at less than usurious rates. Approval in the UK would also match the production capacity with the demand as the company ramps up production capacity with EDEN.

Then application to the FDA makes sense, until then there is no point in getting FDA approval for a treatment that can't meet the demand. That would be business malpractice to get FDA approval
before the company has the resources to meet the expected demand.

But you knew all those things.

Well it is interesting he is not talking about science just financial. Saying bankruptcy. Well someone needs to tell that idiot he is 4 years late. He could have said something like that in the past. We have passed that line and heading to successful results with accompany great financials.

Specials was never the answer,...
Yet they spent $13M on it last year and they had Direct trials that other parties would sponsor that cold have been run for chump change.

theorysuit claimed that his investments in other field were great. I feel happy about his claim. Pretty soon he is going to pay us back with his other investments and the interest rate is going to be high.

theorysuit,

The only bankruptcy in this picture is the morally bankrupt person making the accusation and anyone who thinks his way is the right way; ). Best wishes.

Agree

With all these 5 markets it will be a tremendous pressure on FDA to grant an approval in a short time.

It would seem that somebody must be paying him to speak out and comment on NWBO. This is a direct quote from him when asked to comment by a newspaper about his life after prison.

“When contacted by phone, Shkreli said: “I will only comment if you give me significant financial compensation.””

Therefore, IT WOULD BE CONSISTENT WITH That statement, THAT SOMEONE must be giving him significant financial compensation to trash NWBO. That makes sense.

On the "worst CEO list", AF had M Shkreli one behind LP.

I think MS deserves number one. So have to disagree with AF on that.

CaptainObvious,

Now we know we are good as gold!; ). Adam, Martin and Kenny, the trifecta!; ). Best wishes.

He was let out a little early, iirc

Viagra.

Again you are imposing / assuming that “all” others share your view which is far from true . There are several on this board and many I know personally who don’t . But somehow you are implying that you know their views better than they themselves know them .
This is called a cult .